Skip to main content
main-content
Top

TMB and NSCLC outcomes

The focus of one cohort of KEYNOTE-021 and of KEYNOTE-189 is to investigate the addition of pembrolizumab to platinum-based chemotherapy plus pemetrexed in patients with untreated advanced non-small-cell lung cancer. Prior reports from both trials have demonstrated significant improvements in survival outcomes with use of the PD-1 inhibitor.

KEYNOTE-021 study results from from WCLC 2019

Lead researcher Corey Langer explains that the study found no correlation between tumor mutation burden and response, progression-free survival and overall survival in previously untreated advanced nonsquamous non-small cell lung cancer patients treated with pembrolizumab plus platinum-based chemotherapy.


Receive the latest WCLC 2019 news direct to your inbox


Two presentations at WCLC 2019 addressed the role of the tumor mutational burden in predicting response to treatment in these trials.

Title: KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC
Presenter: Corey Langer, University of Pennsylvania, Philadelphia, USA
Sunday, September 8: 16:00–16:10 (Abstract OA04.05)

Title: Evaluation of TMB in KEYNOTE-189: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC
Presenter: Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Sunday, September 8: 16:10–16:20 (Abstract OA04.06)

Back to the WCLC 2019 conference hub